U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H26N2O2.C4H6O4
Molecular Weight 480.5528
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SOLIFENACIN SUCCINATE

SMILES

OC(=O)CCC(O)=O.O=C(O[C@H]1CN2CCC1CC2)N3CCC4=C(C=CC=C4)[C@@H]3C5=CC=CC=C5

InChI

InChIKey=RXZMMZZRUPYENV-VROPFNGYSA-N
InChI=1S/C23H26N2O2.C4H6O4/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19;5-3(6)1-2-4(7)8/h1-9,18,21-22H,10-16H2;1-2H2,(H,5,6)(H,7,8)/t21-,22-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C23H26N2O2
Molecular Weight 362.4647
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C4H6O4
Molecular Weight 118.088
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Solifenacin is a competitive muscarinic acetylcholine receptor antagonist. The binding of acetylcholine to these receptors, particularly the M3 receptor subtype, plays a critical role in the contraction of smooth muscle. By preventing the binding of acetylcholine to these receptors, solifenacin reduces smooth muscle tone in the bladder, allowing the bladder to retain larger volumes of urine. It is FDA approved for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Common adverse reactions include constipation, Xerostomia. Inhibitors of CYP3A4 may increase the concentration of Solifenacin. Vice versa, CYP3A4 Inducers decrease concentration.

CNS Activity

Approval Year

PubMed

PubMed

TitleDatePubMed
Drug forecast--solifenacin: an investigational anticholinergic for overactive bladder.
2004 May
Solifenacin in overactive bladder: a viewpoint by Hashim Hashim.
2005
Solifenacin in overactive bladder syndrome: a viewpoint by Scott Serels.
2005
Solifenacin in overactive bladder syndrome.
2005
Overactive bladder in the elderly: a guide to pharmacological management.
2005
[Drug discovery in the fields of urology: tamsulosin and solifenacin].
2005 Nov
Solifenacin in overactive bladder syndrome.
2006
Gateways to clinical trials.
2006 Apr
The causes and consequences of overactive bladder.
2006 Apr
Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment.
2006 Aug
Solifenacin significantly improves all symptoms of overactive bladder syndrome.
2006 Aug
Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects.
2006 Aug
New developments in the treatment of urinary incontinence.
2006 Dec
Solifenacin succinate (VESIcare): overactive bladder therapy.
2006 Dec
Open-label study of the safety and pharmacokinetics of solifenacin in subjects with hepatic impairment.
2006 Dec
[Pharmacological and clinical profile of solifenacin succinate (Vesicare) developed as a new therapeutic agent for overactive bladder].
2006 Dec
Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder.
2006 Dec
Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder.
2006 Dec
Newer agents for the management of overactive bladder.
2006 Dec 15
Muscarinic receptors in the bladder: from basic research to therapeutics.
2006 Feb
New drugs 06, part I.
2006 Feb
Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis.
2006 Jan
Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers.
2006 Jul
Comparative evaluation of exocrine muscarinic receptor binding characteristics and inhibition of salivation of solifenacin in mice.
2006 Jul
[Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].
2006 Jul
[Oral anticholinergics in overactive bladder].
2006 Jul
Gateways to clinical trials.
2006 Jul-Aug
Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence.
2006 Jun
Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
2006 Mar
The emergence of new drugs for overactive bladder.
2006 Mar
Management of overactive bladder and urge urinary incontinence in the elderly patient.
2006 Mar
Pharmacologic management of overactive bladder: practical options for the primary care physician.
2006 Mar
Using anticholinergics to treat overactive bladder: the issue of treatment tolerability.
2006 Mar
Gateways to clinical trials.
2006 May
Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
2006 Nov
Gateways to clinical trials.
2006 Nov
Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?
2006 Nov
Solifenacin.
2006 Nov
Anticholinergic drugs versus placebo for overactive bladder syndrome in adults.
2006 Oct 18
Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis.
2006 Sep
Solifenacin succinate for the treatment of symptoms of overactive bladder.
2006 Sep
Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin.
2006 Sep
Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test.
2007 Feb 28
Pharmacokinetics, safety, and tolerability of solifenacin in patients with renal insufficiency.
2007 Jan
Redefining response in overactive bladder syndrome.
2007 Jan
Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
2007 Jan
Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms.
2007 Jul
Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
2007 Mar
An unusual cause of postoperative detrusor overactivity.
2007 Oct
Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride.
2007 Sep
Patents

Sample Use Guides

In Vivo Use Guide
5 mg tablet taken once daily, and if well tolerated may be increased to 10 mg once daily.
Route of Administration: Oral
In Vitro Use Guide
The inhibitory effect of solifenacin (dose range: 10^-10 - 10^-6 M) for bladder smooth muscle cells (pK(i)=8.12) was 3.6-fold more potent than that for salivary gland cells (pK(i)=7.57).
Substance Class Chemical
Created
by admin
on Tue Oct 22 00:03:53 UTC 2019
Edited
by admin
on Tue Oct 22 00:03:53 UTC 2019
Record UNII
KKA5DLD701
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SOLIFENACIN SUCCINATE
JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN  
Official Name English
YM67905
Code English
SOLIFENACIN SUCCINATE [USAN]
Common Name English
YM905
Code English
YM-67905
Code English
YM-905
Code English
SOLIFENACIN SUCCINATE [VANDF]
Common Name English
SOLIFENACIN SUCCINATE [ORANGE BOOK]
Common Name English
SOLIFENACIN SUCCINATE [MI]
Common Name English
SOLIFENACIN SUCCINATE [JAN]
Common Name English
SOLIFENACIN SUCCINATE [MART.]
Common Name English
VESICARE
Brand Name English
SOLIFENACIN SUCCINATE [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29704
Created by admin on Tue Oct 22 00:03:54 UTC 2019 , Edited by admin on Tue Oct 22 00:03:54 UTC 2019
Code System Code Type Description
RXCUI
477365
Created by admin on Tue Oct 22 00:03:54 UTC 2019 , Edited by admin on Tue Oct 22 00:03:54 UTC 2019
ALTERNATIVE
NCI_THESAURUS
C73805
Created by admin on Tue Oct 22 00:03:54 UTC 2019 , Edited by admin on Tue Oct 22 00:03:54 UTC 2019
PRIMARY
MERCK INDEX
M10108
Created by admin on Tue Oct 22 00:03:54 UTC 2019 , Edited by admin on Tue Oct 22 00:03:54 UTC 2019
PRIMARY Merck Index
PUBCHEM
216457
Created by admin on Tue Oct 22 00:03:54 UTC 2019 , Edited by admin on Tue Oct 22 00:03:54 UTC 2019
PRIMARY
EVMPD
SUB21028
Created by admin on Tue Oct 22 00:03:54 UTC 2019 , Edited by admin on Tue Oct 22 00:03:54 UTC 2019
PRIMARY
MESH
C441209
Created by admin on Tue Oct 22 00:03:54 UTC 2019 , Edited by admin on Tue Oct 22 00:03:54 UTC 2019
PRIMARY
RXCUI
476588
Created by admin on Tue Oct 22 00:03:54 UTC 2019 , Edited by admin on Tue Oct 22 00:03:54 UTC 2019
PRIMARY
CAS
242478-38-2
Created by admin on Tue Oct 22 00:03:54 UTC 2019 , Edited by admin on Tue Oct 22 00:03:54 UTC 2019
PRIMARY
ChEMBL
CHEMBL1734
Created by admin on Tue Oct 22 00:03:54 UTC 2019 , Edited by admin on Tue Oct 22 00:03:54 UTC 2019
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY